2021
DOI: 10.1016/j.phrs.2021.105436
|View full text |Cite
|
Sign up to set email alerts
|

COL1A1 as a potential new biomarker and therapeutic target for type 2 diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
18
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 28 publications
(21 citation statements)
references
References 42 publications
3
18
0
Order By: Relevance
“…Neutrophil degranulation [52], innate immune system [53], platelet degranulation [54], extracellular matrix organization [55], diseases of glycosylation [56], platelet activation, signaling and aggregation [57], hemostasis [58], secretion [59], secretory vesicle [60], transmembrane transporter activity [61], cell adhesion [62], localization of cell [63], extracellular matrix [55], intrinsic component of plasma membrane [64], structural molecule activity [65], signaling receptor binding [66], have been highly noted in T2DM. Reports indicate that HIF1A [67], HLA-DRB1 [68], CHI3L1 [69], ADORA2A [70], ADRB2 [71], CLU (clusterin) [72], AGT (angiotensinogen) [73], VCAM1 [74], PPARA (peroxisome proliferator activated receptor alpha) [75], APOL1 [76], ZFP36 [77], PPM1B [78], SOCS1 [79], SNCA (synuclein alpha) [80], CTSS (cathepsin S) [81], IL6R [82], CFB (complement factor B) [83], DEFB1 [84], VNN1 [85], RAB27A [86], DPP4 [87], RARRES2 [88], CASP1 [89], LCN2 [90], REG3A [91], CD74 [92], PCSK2 [93], CHGB (chromogranin B) [94], TTR (transthyretin) [95], LRG1 [96], ALB (albumin) [97], DPP7 [98], APOH (apolipoprotein H) [99], CTSD (cathepsin D) [100], GCG (glucagon) [101], KCNQ1 [102], NR4A1 [103], PLIN5 [104], ALDH2 [105], ANG (angiogenin) [106], CLDN7 [107], PRLR (prolactin receptor) [108], SOD2 [109], MLXIPL (MLX interacting protein like) [110], CTSD (cathepsin D) [111], PECAM1 [112], ADA (adenosine deaminase) [113], MFGE8 [114], COL1A1 [115], COL3A1 [116], NID2 [117], ARG1 [118], CD93 [119], IGF2 […”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Neutrophil degranulation [52], innate immune system [53], platelet degranulation [54], extracellular matrix organization [55], diseases of glycosylation [56], platelet activation, signaling and aggregation [57], hemostasis [58], secretion [59], secretory vesicle [60], transmembrane transporter activity [61], cell adhesion [62], localization of cell [63], extracellular matrix [55], intrinsic component of plasma membrane [64], structural molecule activity [65], signaling receptor binding [66], have been highly noted in T2DM. Reports indicate that HIF1A [67], HLA-DRB1 [68], CHI3L1 [69], ADORA2A [70], ADRB2 [71], CLU (clusterin) [72], AGT (angiotensinogen) [73], VCAM1 [74], PPARA (peroxisome proliferator activated receptor alpha) [75], APOL1 [76], ZFP36 [77], PPM1B [78], SOCS1 [79], SNCA (synuclein alpha) [80], CTSS (cathepsin S) [81], IL6R [82], CFB (complement factor B) [83], DEFB1 [84], VNN1 [85], RAB27A [86], DPP4 [87], RARRES2 [88], CASP1 [89], LCN2 [90], REG3A [91], CD74 [92], PCSK2 [93], CHGB (chromogranin B) [94], TTR (transthyretin) [95], LRG1 [96], ALB (albumin) [97], DPP7 [98], APOH (apolipoprotein H) [99], CTSD (cathepsin D) [100], GCG (glucagon) [101], KCNQ1 [102], NR4A1 [103], PLIN5 [104], ALDH2 [105], ANG (angiogenin) [106], CLDN7 [107], PRLR (prolactin receptor) [108], SOD2 [109], MLXIPL (MLX interacting protein like) [110], CTSD (cathepsin D) [111], PECAM1 [112], ADA (adenosine deaminase) [113], MFGE8 [114], COL1A1 [115], COL3A1 [116], NID2 [117], ARG1 [118], CD93 [119], IGF2 […”
Section: Discussionmentioning
confidence: 99%
“…A total of 925 DEGs (447 up regulated genes and 478 down regulated genes) were screened between T2DM and control samples. Emmens et al [39] found that PENK [110], CTSD (cathepsin D) [111], PECAM1 [112], ADA (adenosine deaminase) [113], MFGE8 [114], COL1A1 [115], COL3A1 [116], NID2 [117], ARG1 [118], CD93 [119], IGF2 [120], IL18 [121], LAMA1 [122], HPSE (heparanase) [123], BMP4 [124] [132], MMP3 [133], MMP9 [134], MMP11 [135], IL16 [136], TNFRSF11B [137], TIMP3 [138] and CAPN3 [139] were found in T2DM. HLA-A [140], HLA-B [141], HLA-C [142], HLA-DPB1 [143], HLA-E [144], ERBB3 [145], MFAP4 [146] and JAK3 [147] have been reported significantly expressed in type 1 diabetes mellitus, but these genes might be involved in T2DM progression.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Based on previous studies, CD248 is generally associated with progression of hypertension [34], but this gene might be linked with development of GDM. Lin et al [35] reported that expression of COL1A1 was essential for type 2 diabetes mellitus progression, but this gene might be involved in the development of GDM. Delfín et al [36] found that ABI3BP was responsible for progression of cardiovascular diseases, but this gene might be linked with development of GDM.…”
Section: Discussionmentioning
confidence: 99%
“…Forty male ICR mice (SPF, 4 weeks age) were supplied by Wu Shi’s Experimental Center Laboratory (Fuzhou, China), and they were raised under a condition of 23 ± 2 °C, a humidity of 55 ± 5%, and 12 h light/dark cycle. After one week of acclimation with food and water ad libitum, eight mice fed a normal diet were assigned to the normal control (NC, n = 8) group, and the rest of the thirty-two mice were fed with a high-fat and high-sucrose (HFHS) diet (15% lard, 15% sucrose, 1% cholesterol, 10% yolk, 0.2% sodium deoxycholate, and 58.8% chow) [ 36 ]. After 4 weeks of diet intervention, the mice with HFHS diet were intraperitoneally injected streptozotocin (STZ, dissolved in 0.1 M citrate buffer, pH 4.5) at a dose of 45 mg/kg, whereas the NC group mice were injected with the same volume of citrate buffer for three times a week.…”
Section: Methodsmentioning
confidence: 99%